Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386881796> ?p ?o ?g. }
- W4386881796 abstract "Acute megakaryoblastic leukemia (AMKL) is a rare, developmentally restricted and highly lethal cancer of early childhood. The paucity and hypocellularity (due to myelofibrosis) of primary patient samples hamper the discovery of cell- and genotype-specific treatments. AMKL is driven by mutually exclusive chimeric fusion oncogenes in two thirds of cases, with CBFA2T3::GLIS2 (CG2) and NUP98 fusions (NUP98r) representing the highest fatality subgroups. We established CD34+ cord blood-derived CG2 models (n=6) that sustain serial transplantation and recapitulate human leukemia regarding immunophenotype, leukemia initiating cell frequencies, co-mutational landscape and gene expression signature with distinct upregulation of the pro-survival factor BCL2. Cell membrane proteomic analyses highlighted CG2 surface markers preferentially expressed on leukemic cells compared to CD34+ cells (e.g. NCAM1, CD151). AMKL differentiation block in the mega-erythroid progenitor space was confirmed by single cell profiling. While CG2 cells were rather resistant to BCL2 genetic knockdown or selective pharmacological inhibition with Venetoclax, they were vulnerable to strategies that target the megakaryocytic pro-survival factor BCL-XL (BCL2L1), including in vitro and in vivo treatment with BCL2/BCL-XL/BCL-W inhibitor Navitoclax and DT2216, a selective BCL-XL PROTAC (proteolysis-targeting chimera) degrader developed to limit thrombocytopenia in patients. NUP98r AMKL were also sensitive to BCL-XL inhibition, but not the NUP98r monocytic leukemia, pointing to a lineage-specific dependency. Navitoclax or DT2216 treatment in combination with low dose cytarabine further reduced leukemic burden in mice. This work extends the cellular and molecular diversity set of human AMKL models and uncovers BCL-XL as a therapeutic vulnerability in CG2 and NUP98r AMKL." @default.
- W4386881796 created "2023-09-21" @default.
- W4386881796 creator A5008391771 @default.
- W4386881796 creator A5009187210 @default.
- W4386881796 creator A5009642426 @default.
- W4386881796 creator A5024634771 @default.
- W4386881796 creator A5025236528 @default.
- W4386881796 creator A5026939464 @default.
- W4386881796 creator A5028885623 @default.
- W4386881796 creator A5030783443 @default.
- W4386881796 creator A5032789799 @default.
- W4386881796 creator A5034413134 @default.
- W4386881796 creator A5038131650 @default.
- W4386881796 creator A5038888195 @default.
- W4386881796 creator A5041608515 @default.
- W4386881796 creator A5046333227 @default.
- W4386881796 creator A5046629230 @default.
- W4386881796 creator A5047850008 @default.
- W4386881796 creator A5048753753 @default.
- W4386881796 creator A5051501697 @default.
- W4386881796 creator A5053604124 @default.
- W4386881796 creator A5056795230 @default.
- W4386881796 creator A5058795992 @default.
- W4386881796 creator A5058935043 @default.
- W4386881796 creator A5059301202 @default.
- W4386881796 creator A5061951514 @default.
- W4386881796 creator A5065340339 @default.
- W4386881796 creator A5067151632 @default.
- W4386881796 creator A5067528740 @default.
- W4386881796 creator A5069869744 @default.
- W4386881796 creator A5072106083 @default.
- W4386881796 creator A5073245971 @default.
- W4386881796 creator A5074098824 @default.
- W4386881796 creator A5081616530 @default.
- W4386881796 creator A5082883166 @default.
- W4386881796 creator A5090035556 @default.
- W4386881796 creator A5090546289 @default.
- W4386881796 creator A5090594300 @default.
- W4386881796 creator A5090882174 @default.
- W4386881796 date "2023-09-20" @default.
- W4386881796 modified "2023-10-18" @default.
- W4386881796 title "CBFA2T3::GLIS2 Pediatric Acute Megakaryoblastic Leukemia is Sensitive to BCL-XL Inhibition by Navitoclax and DT2216" @default.
- W4386881796 doi "https://doi.org/10.1182/bloodadvances.2022008899" @default.
- W4386881796 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37729615" @default.
- W4386881796 hasPublicationYear "2023" @default.
- W4386881796 type Work @default.
- W4386881796 citedByCount "0" @default.
- W4386881796 crossrefType "journal-article" @default.
- W4386881796 hasAuthorship W4386881796A5008391771 @default.
- W4386881796 hasAuthorship W4386881796A5009187210 @default.
- W4386881796 hasAuthorship W4386881796A5009642426 @default.
- W4386881796 hasAuthorship W4386881796A5024634771 @default.
- W4386881796 hasAuthorship W4386881796A5025236528 @default.
- W4386881796 hasAuthorship W4386881796A5026939464 @default.
- W4386881796 hasAuthorship W4386881796A5028885623 @default.
- W4386881796 hasAuthorship W4386881796A5030783443 @default.
- W4386881796 hasAuthorship W4386881796A5032789799 @default.
- W4386881796 hasAuthorship W4386881796A5034413134 @default.
- W4386881796 hasAuthorship W4386881796A5038131650 @default.
- W4386881796 hasAuthorship W4386881796A5038888195 @default.
- W4386881796 hasAuthorship W4386881796A5041608515 @default.
- W4386881796 hasAuthorship W4386881796A5046333227 @default.
- W4386881796 hasAuthorship W4386881796A5046629230 @default.
- W4386881796 hasAuthorship W4386881796A5047850008 @default.
- W4386881796 hasAuthorship W4386881796A5048753753 @default.
- W4386881796 hasAuthorship W4386881796A5051501697 @default.
- W4386881796 hasAuthorship W4386881796A5053604124 @default.
- W4386881796 hasAuthorship W4386881796A5056795230 @default.
- W4386881796 hasAuthorship W4386881796A5058795992 @default.
- W4386881796 hasAuthorship W4386881796A5058935043 @default.
- W4386881796 hasAuthorship W4386881796A5059301202 @default.
- W4386881796 hasAuthorship W4386881796A5061951514 @default.
- W4386881796 hasAuthorship W4386881796A5065340339 @default.
- W4386881796 hasAuthorship W4386881796A5067151632 @default.
- W4386881796 hasAuthorship W4386881796A5067528740 @default.
- W4386881796 hasAuthorship W4386881796A5069869744 @default.
- W4386881796 hasAuthorship W4386881796A5072106083 @default.
- W4386881796 hasAuthorship W4386881796A5073245971 @default.
- W4386881796 hasAuthorship W4386881796A5074098824 @default.
- W4386881796 hasAuthorship W4386881796A5081616530 @default.
- W4386881796 hasAuthorship W4386881796A5082883166 @default.
- W4386881796 hasAuthorship W4386881796A5090035556 @default.
- W4386881796 hasAuthorship W4386881796A5090546289 @default.
- W4386881796 hasAuthorship W4386881796A5090594300 @default.
- W4386881796 hasAuthorship W4386881796A5090882174 @default.
- W4386881796 hasBestOaLocation W43868817961 @default.
- W4386881796 hasConcept C109159458 @default.
- W4386881796 hasConcept C203014093 @default.
- W4386881796 hasConcept C2778041864 @default.
- W4386881796 hasConcept C2778378607 @default.
- W4386881796 hasConcept C2778461978 @default.
- W4386881796 hasConcept C2778729363 @default.
- W4386881796 hasConcept C28328180 @default.
- W4386881796 hasConcept C502942594 @default.
- W4386881796 hasConcept C86803240 @default.
- W4386881796 hasConcept C95444343 @default.
- W4386881796 hasConceptScore W4386881796C109159458 @default.
- W4386881796 hasConceptScore W4386881796C203014093 @default.
- W4386881796 hasConceptScore W4386881796C2778041864 @default.
- W4386881796 hasConceptScore W4386881796C2778378607 @default.